Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005, 149(2):437-440 | DOI: 10.5507/bp.2005.076
ANTITUMOR DRUG ELLIPTICINE INHIBITS THE ACTIVITIES OF RAT HEPATIC CYTOCHROMES P450
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic
Ellipticine is a potent antineoplastic agent, whose mode of action is considered to be based mainly on DNA intercalation and/or inhibition of topoisomerase II. Recently, we found that ellipticine also forms the cytochrome P450 (CYP)-mediated covalent DNA adducts. Here, we study the effect of ellipticine on CYP enzymes in rat hepatic microsomes, studying its binding to the enzymes and its potential to inhibit the CYP activities measured with their selective substrates. Although ellipticine was reported to be a selective and strong inhibitor of CYP1A1/2, we found that its inhibitory potential is non-specific. Ellipticine is the most potent inhibitor for CYP3A-dependent 6β-hydroxylation of progesterone, followed by CYP1A1/2-dependent ethoxyresorufin O-deethylation and CYP2B-mediated pentoxyresorufin O-depentylation. Lower inhibition was detected for 1'-hydroxylation of bufurarol, 21-hydroxylation of progesterone and 6-hydroxylation of chlorzoxazone catalyzed by CYP2D, CYP2C and CYP2E1, respectively. Ellipticine binds to several CYPs of rat hepatic microsomes. The binding titration of ellipticine typically give reverse type I spectrum with CYPs in rat hepatic microsomes. The results indicate that inhibition of CYPs by ellipticine cannot be explained only by its differential potency to bind to individual CYPs.
Keywords: Ellipticine, Anticancer drug, Cytochrome P450, Inhibition, Binding
Received: June 10, 2005; Accepted: September 25, 2005; Published: December 1, 2005 Show citation
References
- Stiborová M, Bieler CA, Wiessler M, Frei E. (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62, 1675-84.
Go to original source...
Go to PubMed...
- Rigaudy P, Charcosset J-Y, Garbay-Jaureguiberry Ch, Jacquemin- Sablon A, Roques BP. (1989) Attempts to target antitumor drugs towards opioid receptor-rich mouse tumor cells with enkephalinellipticinium conjugates. Cancer Res 49,1836-42.
- Devraj R, Barret JF, Fernandez JA, Katzenellenbogen JA, Cushman M. (1996) Design, synthesis and biological evaluation of ellipticineestradiol conjugates. J Med Chem 39, 3367-74.
Go to original source...
Go to PubMed...
- Czerwinski G, Tarasova NI, Michejda CJ. (1998) Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug. Proc Natl Acad Sci USA 95,11520-5.
Go to original source...
Go to PubMed...
- Auclair C. (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259, 1-14.
Go to original source...
Go to PubMed...
- Singh MP, Hill GC, Peoch D, Rayner, B, Inabach, JL, Lown JW. (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 10271-85.
Go to original source...
Go to PubMed...
- Chu Y, Hsu MT. (1992) Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res 20, 4033-8.
Go to original source...
Go to PubMed...
- Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek JJr, Fermandjian S. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25, 1820-9.
Go to original source...
- Fossé P, René B, Charra M, Paoletti C, Saucier JM. (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42, 590-5.
- Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270, 14998-5004.
Go to original source...
Go to PubMed...
- Ohashi M, Sugikawa E, Nakanishi N. (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86, 819-29.
Go to original source...
Go to PubMed...
- Schwaller MA. Allard B, Lescot E and Moreau F. (1995) Protonophoric activity of ellipticine and isomers across the energy- transducing membrane of mitochondria. J Biol Chem 270, 22709-13.
Go to original source...
Go to PubMed...
- Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16, 38-47.
Go to original source...
Go to PubMed...
- Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. (2003) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107, 885-90.
Go to original source...
Go to PubMed...
- Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 6, 8374-80.
Go to original source...
Go to PubMed...
- Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64, 289-95.
Go to original source...
Go to PubMed...
- Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. (1999) Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design 14, 473-86.
Go to PubMed...
- Aimová D, Dlouhá T, Frei E, Stiborová M. Anticancer drug ellipticine acts as an inducer of CYP1A1/2 and potentiates its own pharmacological efficiency. In: Anzenbacher P and Hudecek J, editors. Cytochrome P450, Biochemistry, Biophysics and Drug Metabolism.. Bologna: Monduzzi Editore, 2003. p. 133-8.
- Stiborová M, Bořek-Dohalská L, Hodek P, Mráz J, Frei E. (2002) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 403, 41-9.
Go to original source...
Go to PubMed...
- Bořek-Dohalská L, Hodek P, ©ulc M, Stiborová M. (2001) - Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem-Biol Interact 138, 85-106.
Go to original source...
Go to PubMed...